Doximity's AI Pop Was Real-But After a 130% Spike, I'm Waiting for a Better Price

Doximity's rerating happened fast

I'm waiting for a better price. Doximity just executed a move that leaves little room for error: the stock was near its 52-week low of $17.15 one day, then briefly topped $42 in premarket trading after a strong quarter, a guidance raise, and a short squeeze. That is a rerating, plain and simple.

The business clearly became more credible on the print. Doximity reported $156.6 million in revenue and $74.8 million in adjusted EBITDA, then lifted its fiscal 2027 revenue range to $671 million to $681 million. But at this point, the issue is valuation and timing, not whether the quarter was decent. A stock that moves from badly discounted to breakthrough in one session stops offering much margin for error.

That is the tension investors face now. Bulls can point to real-world utility and early traction, with RBC highlighting AI-driven client engagement in its legacy business alongside the guidance raise. Bears can point to the fact that part of the move was driven by short covering. My view: the quarter was strong, but after a move this large, waiting for a cleaner entry is reasonable.

That matters because many AI stories weaken when you press on who pays, how much each request costs, and whether economics improve over time. On that point, Doximity looks better than a lot of headline-driven names. The remaining question is whether this becomes a meaningful revenue stream or stays a promising feature.

User growth matters more than the marketing headline

Adoption is at least partly showing up in the numbers. Doximity posted a tenfold jump in monthly Scribe users, a useful sign that at least one AI tool is gaining traction with users.

There was also a top ranking in an independent clinical safety study, while bears can note that the NOHARM benchmark was contested. I would not overstate the safety angle, but in clinical AI it still matters. If adoption and perceived safety both hold up, Doximity may have a real moat. If not, the stock may struggle to justify premium assumptions.

Why I still prefer to wait after the pop

I'm still waiting. Doximity was near its 52-week low before the market suddenly had proof the quarter was better than feared, and the breakout was helped because short sellers had to unwind a sizable bet. That strengthens the story, but it also means much of the easy rerating is already in the stock.

The next test is whether Doximity can trade like a fundamentally improving business rather than a dramatic one-day repricing. I would rather wait for a cleaner setup than chase a move that still carries squeeze dynamics.

What investors should watch next

For now, the key watchpoints are straightforward:

• Whether the company converts early AI traction into visible, sustained revenue growth
• Whether AI search economics remain favorable as usage scales
• Whether product adoption, especially around Scribe, continues to build
• Whether safety and trust remain sufficient for broader clinical adoption

After a surge of this size, patience is not skepticism for its own sake. It is just a search for margin of safety.